briovaRx®

Fax:

Phone:

# Hepatitis C Enrollment Form

## PATIENT INFORMATION

*Please complete the following or **send patient demographic sheet***

Patient Name _____

DOB _____ Last Four of SS# _____ Gender _____

Weight _____ Height _____ Phone _____

Address _____

City, State, ZIP _____

Language Preference: ☐ English ☐ Spanish ☐ Other _____

## PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____ NPI _____

Group/Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

## INSURANCE INFORMATION *(Must fax a copy of patient's insurance card including both sides)*

Prior Authorization Reference number _____

## MEDICAL INFORMATION *(Section must be completed to process prescription)* *(Attach separate sheet if needed)*

☐ B18.2 Chronic Hepatitis C ☐ K72.90 Hepatic failure, unspecified without coma ☐ C22.0 Liver Cell Carcinoma

☐ Other Diagnosis: ICD-10 Code _____ Description _____

Genotype _____ Viral Load _____ IU/ml Viral Load Date _____ HIV Coinfected: ☐ Yes ☐ No HBV Coinfected: ☐ Yes ☐ No

Previous therapy history: Naïve _____ Relapsed _____ Partial Responder _____ Null _____

Date(s) of previous therapy and meds _____

Cirrhosis: ☐ Yes ☐ No ☐ Compensated OR ☐ Decompensated Fibrosis Score _____

Liver Transplant: ☐ Yes ☐ No Waiting for Liver Transplant: ☐ Yes ☐ No

**Please include hard copies of: genotype, viral load, liver biopsy scans, CBC, CMP, HIV, PT/INR, H&P, NS5A resistance testing and pertinent office visit notes.**

## PRESCRIPTION INFORMATION

☐ **EPCLUSA** (sofosbuvir 400mg/velpatasvir 100mg) disp. 28 Sig: 1 tablet daily Refill: x _____ Total duration of therapy _____ Weeks

☐ **HARVONI®** (ledipasvir 90mg/sofosbuvir 400mg) disp. 28 Sig: 1 tablet daily Refill: x _____ Total duration of therapy _____ Weeks

☐ **MAVYRET™** (glecaprevir 100mg/pibrentasvir 40mg) disp 84 Refill: x _____ Total duration of therapy _____ Weeks

Sig: Take 3 tablets (contents of one daily dose card) by mouth once daily with food.

**RIBAVIRIN 200mg:**

Directions _____

Quantity _____

Refill: x _____ Total duration of therapy _____ Weeks

☐ < 75kg = 1000mg/day

☐ ≥ 75kg = 1200mg/day

**RIBAPAK (28 day supply):**

☐ 1200mg daily/600mg QAM—600mg QPM

☐ 1000mg daily/600mg QAM—400mg QPM

☐ 800mg daily/400mg QAM—400mg QPM

☐ 600mg daily/200mg QAM—400mg QPM

Refill: x _____ Total duration of therapy _____ Weeks

**MODERIBA (28 day supply):**

☐ 1200mg daily/600mg QAM—600mg QPM

☐ 1000mg daily/600mg QAM—400mg QPM

☐ 800mg daily/400mg QAM—400mg QPM

☐ 600mg daily/200mg QAM—400mg QPM

Refill: x _____ Total duration of therapy _____ Weeks

☐ **SOVALDI™** (sofosbuvir) 400mg disp. 28 Sig: 400mg daily Refill: x _____ Total duration of therapy _____ Weeks

☐ **VOSEVI** Disp. 28 day supply Sig: Take once daily with food Refill: x _____ Total duration of therapy _____ Weeks

☐ **ZEPATIER** (elbasvir 50mg/grazoprevir 100mg) disp. 28 Refill: x _____ duration of therapy _____ Weeks

Sig: Take 1 tablet daily with or without food. ☐ NS5A resistance testing included

**Supportive Therapy:** ☐ **PROMACTA* PO QD** ☐ 12.5mg tablets ☐ 25mg tablets ☐ 50mg tablets ☐ 75mg tablets ☐ 100mg tablets

Quantity _____ Refill: x _____ Total duration of therapy _____ Weeks ***Titrate based on platelet count not to exceed 100mg PO QD**

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office First Fill (future fills to Patient) ☐ Office ALL fills ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____